The "Cholestatic Pruritus - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report outlays comprehensive insights of present clinical development scenarios and growth prospects across the Cholestatic Pruritus market. A detailed picture of the Cholestatic Pruritus pipeline landscape is provided, which includes the disease overview and Cholestatic Pruritus treatment guidelines.
The assessment part of the report embraces in-depth Cholestatic Pruritus commercial assessment and clinical assessment of the Cholestatic Pruritus pipeline products from the pre-clinical developmental phase to the marketed phase.
In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cholestatic Pruritus collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
The report provides insights into:
- All of the companies that are developing therapies for the treatment of Cholestatic Pruritus with aggregate therapies developed by each company for the same.
- Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Cholestatic Pruritus treatment.
- Cholestatic Pruritus key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Cholestatic Pruritus market.
Scope of the Report
- The Cholestatic Pruritus report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Cholestatic Pruritus across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises detailed profiles of Cholestatic Pruritus therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Cholestatic Pruritus research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Cholestatic Pruritus.
Key Topics Covered
1. Report Introduction
2. Cholestatic Pruritus
2.3. Cholestatic Pruritus Symptoms
2.6. Cholestatic Pruritus Diagnosis
2.6.1. Diagnostic Guidelines
3. Cholestatic Pruritus Current Treatment Patterns
3.1. Cholestatic Pruritus Treatment Guidelines
4. Cholestatic Pruritus - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Cholestatic Pruritus companies collaborations, Licensing, Acquisition - Deal Value Trends
126.96.36.199. Assessment Summary
4.1.2. Cholestatic Pruritus Collaboration Deals
188.8.131.52. Company-Company Collaborations (Licensing / Partnering) Analysis
184.108.40.206. Company-University Collaborations (Licensing / Partnering) Analysis
220.127.116.11. Cholestatic Pruritus Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
18.104.22.168. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
22.214.171.124. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
126.96.36.199. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
188.8.131.52. Assessment by Stage and MOA
5.1.6. Assessment by Target
184.108.40.206. Assessment by Stage and Target
6. Cholestatic Pruritus Late Stage Products (Phase-III)
7. Cholestatic Pruritus Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Cholestatic Pruritus Discontinued Products
13. Cholestatic Pruritus Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
220.127.116.11. Product Overview
18.104.22.168. Mechanism of action
13.1.2. Research and Development
22.214.171.124. Clinical Studies
13.1.3. Product Development Activities
126.96.36.199. Patent Detail
13.1.4. Tabulated Product Summary
188.8.131.52. General Description Table
14. Cholestatic Pruritus Key Companies
15. Cholestatic Pruritus Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Cholestatic Pruritus Unmet Needs
18. Cholestatic Pruritus Future Perspectives
19. Cholestatic Pruritus Analyst Review
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
- Cara Therapeutics, Inc.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/mv6xr4
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900